Abstract：
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.
摘要：
感染丙型肝炎病毒（HCV）有不良的肝脏，肾,慢性肾脏病（CKD）患者的心血管后果，包括接受透析治疗的患者和接受肾脏移植的患者。自2008年《肾脏疾病：改善全球结果》（KDIGO）HCV指南发表以来，HCV管理取得了重大进展，特别是随着直接作用抗病毒疗法的出现，现在已经使CKD患者的HCV治愈成为可能。此外,诊断技术已经发展到能够进行肝纤维化的非侵入性诊断。因此,工作组对CKD指南中的KDIGOHCV进行了全面审查和更新.本执行摘要重点介绍了指南建议的关键方面。
